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DOI 10.1016/j.ccr.2010.04.023SUMMARYNonsteroidal anti-inflammatory drugs (NSAIDs) exert their anticancer effects through cyclooxygenase-2
(COX-2)-dependent and independent mechanisms. Here, we report that Sulindac, an NSAID, induces
apoptosis by binding to retinoid X receptor-a (RXRa). We identified an N-terminally truncated RXRa (tRXRa)
in several cancer cell lines and primary tumors, which interacted with the p85a subunit of phosphatidylino-
sitol-3-OH kinase (PI3K). Tumor necrosis factor-a (TNFa) promoted tRXRa interaction with the p85a,
activating PI3K/AKT signaling. When combined with TNFa, Sulindac inhibited TNFa-induced tRXRa/p85a
interaction, leading to activation of the death receptor-mediated apoptotic pathway. We designed and
synthesized a Sulindac analog K-80003, which has increased affinity to RXRa but lacks COX inhibitory
activity. K-80003 displayed enhanced efficacy in inhibiting tRXRa-dependent AKT activation and tRXRa
tumor growth in animals.INTRODUCTION
Sulindac sulfide (Sulindac hereafter) (Haanen, 2001) is one of
the early nonsteroidal anti-inflammatory drugs (NSAIDs) known
to inhibit the activities of cyclooxygenases (COXs), of which
COX-1 is constitutively expressed whereas COX-2 is induced
by mitogenic and inflammatory stimuli. The discovery that
regular use of aspirin, an NSAID, reduces the incidence of colon
cancer has provided the impetus to develop NSAIDs for cancer
prevention and treatment (Grosch et al., 2006; Thun et al., 2002).
Sulindac has received extensive attention because of its potent
induction of apoptosis and inhibition of cancer cell growth (Haa-
nen, 2001; Yamamoto et al., 1999; Zhang et al., 2000). NSAIDs
are believed to exert their anticancer effects through inhibitionSignificance
Our results demonstrate that RXRa mediates NSAID Sulinda
tected in cancer cells acts nongenomically to activate the PI3K
which is inhibited by Sulindac. Our finding that Sulindac and T
TNFa-dependent apoptotic pathway offers therapeutic strateg
kine. Our characterizations of RXR-selective Sulindac analog K
be dissociated from its COX inhibition and identify a RXRa-bas
a broad audience of clinicians, cancer biologists, molecular bi
560 Cancer Cell 17, 560–573, June 15, 2010 ª2010 Elsevier Inc.of COX-2, which is often overexpressed in human premalignant
and malignant tissues and plays a role in carcinogenesis.
Compelling evidence, however, also indicates that NSAIDs can
function through COX-2-independent mechanisms (Grosch
et al., 2006; Yamamoto et al., 1999; Zhang et al., 2000). For
example, cells lacking COX-1, COX-2, or both show comparable
sensitivity to NSAID-induced apoptosis, whereas NSAIDs that
do not inhibit COX-2 also induce apoptosis and inhibit carcino-
genesis. Recent evidence that COX-2 inhibition is associated
with increased cardiovascular risk (Fitzgerald, 2004) under-
scores the importance in the identification of non-COX-2 targets,
whichmay lead to strategies for developing improved anticancer
drugs. Although several non-COX-2 targets for NSAIDs have
been reported (Grosch et al., 2006), more efforts to identifyc-induced apoptosis. We provide evidence that tRXRa de-
/AKT pathway and promote cancer cell growth and survival,
NFa synergistically induce apoptosis through activation of
ies to sensitize cancer cells to the killing effect of this cyto-
-80003 demonstrate that Sulindac’s anticancer effects can
ed lead for cancer therapy. These findings should appeal to
ologists, and drug designers.
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needed in order to develop improved target-based drugs for
cancer therapy.
Retinoid X receptor-a (RXRa), a member of the nuclear
receptor superfamily, plays a role in many biological processes
including carcinogenesis (Altucci and Gronemeyer, 2001; Daw-
son and Zhang, 2002). 9-cis-Retinoic acid (9-cis-RA), several
polyunsaturated fatty acids, and the NSAID Etodolac (Kolluri
et al., 2005) can bind to RXRa to regulate different biological
functions. Targretin, a synthetic RXR ligand, is currently used
for treating cutaneous T cell lymphoma (Dawson and Zhang,
2002), demonstrating the suitability of targeting RXRa for cancer
therapy. Consistently, the oncogenic potential of RXRa has been
demonstrated. Genetic disruption ofRXRa enhances tumorigen-
esis (Huang et al., 2002; Li et al., 2001), and RXR binding to PML/
RAR is essential for the development of acute promyelocytic
leukemia (Zeisig et al., 2007; Zhu et al., 2007). In addition, the
RXRa protein level is often reduced in cancer cells and tumor
tissues (Picard et al., 1999; Takiyama et al., 2004; Zhong et al.,
2003), which is in part due to limited proteolytic processing of
RXRa by calpain or cathepsin (Matsushima-Nishiwaki et al.,
1996; Nagaya et al., 1998; Nomura et al., 1999; Takiyama
et al., 2004; Zhong et al., 2003). However, the biological function
of the resulting truncated RXRa (tRXRa) proteins remains
unknown.
The mechanisms by which RXRa regulates diverse biological
functions remain to be fully determined and are expected to be
complex (Kastner et al., 1995; Mangelsdorf and Evans, 1995).
Like other nuclear receptors, RXRa is known to regulate the
transcription of target genes by binding to DNA response
elements. Accumulating evidence, however, indicates that
RXRa may also have extranuclear actions. RXRa resides in the
cytoplasm in certain cell types and at different stages during
development (Fukunaka et al., 2001). It migrates from the
nucleus to the cytoplasm in response to differentiation (Katagiri
et al., 2000), apoptosis (Cao et al., 2004), and inflammation
(Ghose et al., 2004; Zimmerman et al., 2006). Interestingly,
tRXRa resulted from limited proteolytic cleavage in tumor cells
is also cytoplasmic (Zhong et al., 2003). Whether and how it
acts in the cytoplasm to modulate carcinogenesis is currently
unknown.
In this study, we examined whether tRXRa serves as an
intracellular target mediating the apoptotic effect of Sulindac.
In addition, we investigated the mechanism by which cyto-
plasmic tRXRa acts to promote tumor growth. Furthermore,
we explored the possibility to dissociate Sulindac’s anticancer
effects from its COX inhibition activity.
RESULTS
Sulindac Binds to RXRa
We previously reported that R-Etodolac binds RXRa and
induces a RXRa-dependent apoptosis of cancer cells in vitro
and in animals (Kolluri et al., 2005). During the course of identi-
fying other NSAIDs as potential RXRa ligands, we found that
Sulindac bound to RXRa, but not RAR (see Figure S1A available
online), with an IC50 of 80 mM (Figure 1A), which is in its concen-
tration range that induces apoptosis (Yamamoto et al., 1999;
Zhang et al., 2000). High-performance liquid chromatography(HPLC) analysis showed a direct binding of Sulindac to RXRa
protein but not other nuclear receptors such as RAR and
Nur77 in cells (Figure 1B and Figure S1B). The binding was
also illustrated by altered sensitivity of RXRa ligand-binding
domain (LBD) or full-length (fl)-RXRa protein to chymotrypsin
digestion by Sulindac in vitro (Figure 1C). Furthermore, we took
advantage of the presence of fluorine atom in Sulindac and
examined 19F nuclear magnetic resonance (NMR) spectra.
Figure 1D shows that the signal intensity of the fluorine spectrum
of Sulindac was strongly suppressed by RXRa LBD but not
by Nur77 protein, demonstrating a direct and specific binding.
Sulindac binding inhibited transactivation of RXRa homodimers
(Figure 1E) and certain heterodimers (Figure 1F and Figure S1C)
in the reporter assays, demonstrating that Sulindac is a RXRa
transactivation antagonist.
Sulindac Induces RXRa-Dependent Apoptosis
To determine the role of RXRa in Sulindac-induced apoptosis,
we examined its death effect in F9 cells and F9 cells lacking
RXRa (F9-RXRa/). Sulindac induced extensive apoptosis in
F9 cells, but had little effect in F9-RXRa/ cells (Figures 2A–2C).
Moreover, the apoptotic effect of Sulindac was reduced in cells
with diminished RXRa level (Figures 2D and 2E), whereas it
was enhanced in cells with ectopically expressed RXRa in
RXRa-negative CV-1 cells (Figure 2F). To address the role of
Sulindac binding to RXRa, we constructed the RXRa/F313S/
R316E mutant in which Phe313 and Arg316 essential for maintain-
ing the functional integrity of RXRa ligand-binding pocket (LBP)
(Bourguet et al., 2000) were substituted with Ser and Glu,
respectively. The mutant failed to respond to ligand-induced
homodimer or heterodimer transactivation (Figure S2) and
showed reduced apoptotic responses to Sulindac (Figure 2G).
Thus, RXRa is involved in Sulindac-induced apoptosis.
Bax, a proapoptotic Bcl-2 family member, is required for the
apoptotic effect of Sulindac (Zhang et al., 2000). We therefore
determined if RXRa was involved in activation of Bax by Sulin-
dac. Sulindac induced cleavage of PARP (Figure 2H) and
apoptosis (Figure 2I) in HCT116 colon cancer cells, but not in
HCT116 cells lacking Bax (Bax/). The fact that HCT116 cells
are deficient of COX-2 (Sheng et al., 1997) demonstrates that
Sulindac-induced apoptosis can be COX-2 independent. Immu-
noblotting assays showed that Bax underwent extensive
oligomerization on mitochondria in response to Sulindac, which
was abrogated by RXRa siRNA (Figure 2J). In addition, immu-
nostaining using anti-Bax antibody (Bax/D21) and a Bax confor-
mation-sensitive antibody Bax/6A7 (Nechushtan et al., 1999)
demonstrated that Sulindac-induced Bax conformational
change and mitochondrial targeting were impaired by RXRa
siRNA (Figure 2K). Together, these results demonstrate that
RXRa can act as an intracellular target mediating the apoptotic
effect of Sulindac.
Sulindac Inhibits RXRa-Dependent AKT Activation
by TNFa
Activation of phosphatidylinositol-3-OH kinase (PI3K) and its
downstream effector, AKT, regulates the biological function of
substrates such as Bax (Cantley, 2002). We therefore investi-
gated whether Sulindac activated Bax through inhibition of
AKT activation and found that Sulindac potently suppressedCancer Cell 17, 560–573, June 15, 2010 ª2010 Elsevier Inc. 561
Figure 1. Sulindac Binds to RXRa
(A) Sulindac binding to RXRa in vitro. RXRa LBD
protein was incubated with [3H]9-cis-RA in the
presence or absence of Sulindac or unlabeled
9-cis-RA. Bound [3H]9-cis-RA was quantitated
by liquid scintillation counting.
(B) Sulindac binding to RXRa in cells. HEK293 cells
stably expressing RXRa, Nur77 or RARb were
treated with 100 mM Sulindac for 3 hr. The same
amount of purified RXRa, Nur77, or RARb protein
was subjected to HPLC analysis for the presence
of Sulindac.
(C) Altered sensitivity of RXRa LBD or GST-RXRa
to chymotrypsin (mg/ml) by Sulindac (100 mM).
(D) Comparison of 19F NMR spectra of Sulindac
(100 mM) in the absence and presence of 10 mM
RXRa LBD or Nur77 protein.
(E and F) Sulindac inhibits transactivation of RXRa
homodimers and heterodimers. (TREpal)2-tk-CAT
(Zhang et al., 1992a) (E) or bRARE-tk-CAT (Zhang
et al., 1992b) (F), Nur77 and/or RXRa were tran-
siently transfected into CV-1 cells. Cells were
treated with or without SR11237 (106 M) in the
presence or absence of Sulindac. CAT activity
was determined. One of three to five similar exper-
iments is shown. Error bars represent SEM. See
also Figure S1.
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Transfection of RXRa siRNA significantly reduced AKT activation
(Figure 3B), similar to the effect of Sulindac, raising the possibility
that Sulindac might inhibit RXRa-mediated AKT activation.
Although Sulindac failed to inhibit AKT activation induced by
epidermal growth factor (Figure S3A), it potently inhibited AKT
activation induced by retinoic acid in a RXRa-dependent manner
(Figures S3B and S3C).
TNFa could also activate PI3K/AKT signaling (Ozes et al.,
1999; Pincheira et al., 2008). We thus examined whether RXRa
played a role in AKT activation by TNFa. Treatment of A549
lung cancer cells with TNFa led to strong AKT activation, which
was potently inhibited by Sulindac (Figure 3C). Transfection of
RXRa siRNA, which inhibited not only the expression of the
54 kDa fl-RXRa but also a 44 kDa tRXRa, significantly impaired
the ability of TNFa to activate AKT (Figure 3C), demonstrating
that RXRa was critical for AKT activation by TNFa. Although
Sulindac showed little inhibitory effect on AKT activation in
cancer cells with high basal AKT activation, such as ZR-75-1
breast cancer and PC3 prostate cancer cells, it effectively in-562 Cancer Cell 17, 560–573, June 15, 2010 ª2010 Elsevier Inc.hibited AKT activation when used
together with TNFa (Figure 3D), raising
an intriguing possibility that TNFa can
sensitize cancer cells to Sulindac by con-
verting AKT activation from a RXRa-inde-
pendent to a RXRa-dependent manner.
TNFa-Induced Interaction
of tRXRa with p85a and its
Inhibition by Sulindac
Our observations that RXRa was required
for AKT activation by TNFa and retinoicacid prompted us to examine whether RXRa interacted with
p85a. Our initial intensive attempts by coimmunoprecipitation
assays using anti-RXRa antibody (D20) against sequences in the
N terminus of RXRa (Figure 3E) failed to detect a clear interaction,
although the antibody effectively immunoprecipitated the RXRa
protein (Figure S3E). Because tRXRa proteins produced through
limited proteolytic cleavage in cancer cells (Figure 3F) were cyto-
plasmic (Nagaya et al., 1998; Zhong et al., 2003), we asked
whether the cytoplasmic tRXRa was responsible for binding to
p85a. For this purpose, we used another anti-RXRa antibody
(DN197) that recognizes the RXRa LBD (Figure 3E). Indeed, p85a
was readily coimmunoprecipitated by the DN197 antibody in a
TNF-a (Figure3E)orRA(FiguresS3DandS3E)dependentmanner.
Coimmunoprecipitation of p85awas accompanied with immuno-
precipitation of tRXRa, which was not detected by the D20 RXRa
antibody (Figure S3E), indicating its lack of N-terminal sequences.
Using the DN197 antibody, we also observed that interaction of
p85a with tRXRa in the presence of TNF-a (Figure 3E) or 9-cis-
RA (Figure S3D) was inhibited by Sulindac. These results sug-
gested that tRXRamight bind to p85a, leading to AKT activation.
Figure 2. Sulindac Induces RXRa-Dependent Apoptosis and Bax Activation
(A–C) The apoptotic effects of Sulindac in F9 or F9 cells lacking RXRa (F9 RXRa/). Cells treated with Sulindac (75 mM) for 24 hr were analyzed by DAPI staining
(A), PARP cleavage (B), and DNA fragmentation (C). The scale bar represents 10 mm.
(D and E) RXRa siRNA inhibits apoptosis induction by Sulindac. H460 lung cancer cells transfectedwith control or RXRa siRNAwere treatedwith Sulindac (75 mM)
for 24 hr and analyzed by DAPI staining for apoptosis.
(F) Transfection of RXRa enhances the apoptotic effect of Sulindac. CV-1 cells transfected with GFP-RXRa were treated with Sulindac (75 mM) for 24 hr and
analyzed by DAPI staining. GFP-RXRa-transfected cells underwent extensive nuclear fragmentation and condensation.
(G) Disruption of the RXRa LBP impairs the apoptotic effect of Sulindac. CV-1 cells transfected with GFP-RXRa or GFP-RXRa/F313S/R316E were treated with
Sulindac (75 mM) for 24 hr and analyzed by DAPI staining. Apoptosis scored in receptor-transfected cells. See also Figure S2.
(H and I) Role of Bax in apoptosis induction by Sulindac. HCT116 cells or HCT116 cells lackingBax (Bax/) were treatedwith or without Sulindac (75 mM) for 24 hr.
Apoptosis determined by PARP cleavage (H) and DAPI staining (I).
(J and K) RXRa siRNA inhibits Sulindac-induced Bax activation. Knocking down RXRa in HCT116 cells by RXRa siRNA revealed by immunoblotting. HCT116 cells
transfected with or without RXRa siRNA or control siRNA for 48 hr were treated with Sulindac for 6 hr, and analyzed for Bax oligomerization (J) and Bax
conformational change and mitochondrial targeting by immunostaining/confocal microscopy using Bax/D21, Bax/6A7, or anti-Hsp60 antibody (K). About
60% of cells showed Bax conformational change presented. One of three to five similar experiments is shown. Error bars represent SEM.
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Figure 3. Sulindac Inhibits TNFa-Induced
AKT Activation and tRXRa-p85a Interaction
(A) Inhibition of AKT activation by Sulindac. The
indicated cells starved overnight and treated with
Sulindac (100 mM) for 1 hr were analyzed for AKT
activation by immunoblotting.
(B) Inhibition of basal AKT activation by RXRa
siRNA. HepG2 cells transfected with RXRa siRNA
for 48 hr were treated with Sulindac (100 mM) for
1 hr. AKT activation and RXRa expression were
analyzed by immunoblotting.
(C) Inhibition of TNFa-induced AKT activation by
Sulindac and RXRa siRNA. A549 lung cancer cells
transfected with RXRa or control siRNA for 48 hr
were pretreated with Sulindac (100 mM) for 1 hr
before exposed to TNFa (10 ng/ml) for 30 min.
(D) Synergistic inhibition of AKT activation by TNFa
and Sulindac. ZR-75-1 and PC3 cells were pre-
treated with Sulindac for 1 hr before exposed to
TNFa (10 ng/ml) for 30 min.
(E) Induction of RXRa-p85a interaction by TNFa.
A549 cells treated with TNFa (10 ng/ml) and/or
Sulindac (100 mM) for 30 min were analyzed for
RXRa-p85a interaction by coimmunoprecipitation
using DN197 antibody. The top portion shows
a schematic representation of anti-RXRa anti-
bodies used in coimmunoprecipitation and immu-
noblotting assays. D20 antibody recognizes amino
acids 2-21 in the N-terminal A/B domain, while
DN197 antibody recognizes the C-terminal E/F
domain. A RXRa truncated protein with about
44 kDa is also shown.
(F) Expression of tRXRa in various cancer cell
lines. The indicated cell lines treated with or
without 9-cis-RA (107 M) for 30 min were
analyzed by immunoblotting using the DN197
RXRa antibody. One of three to six similar experi-
ments is shown. See also Figure S3.
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of AKT
We reported previously that cell density plays a critical role in
determining the cytoplasmic localization of RARg (Han et al.,
2009). We similarly observed that the level of the 44 kDa tRXRa
reduced as the density of cells increased, which was accompa-
nied with production of a smaller RXRa fragment. Interestingly,
the levels of the 44 kDa tRXRa protein correlated with AKT
activation (Figure 4A), suggesting that cell density-dependent
proteolytic cleavage of RXRamight be an important mechanism
regulating AKT activation. Consistent with cytoplasmic localiza-
tion of tRXRa (Figure S4A), immunostaining of MEFs with the
DN197 antibody revealed RXRa staining predominantly in the
cytoplasm and occasionally on the plasma membrane
(Figure 4B), likely due to the high levels of tRXRa in MEFs.
Thus, deletion of the N-terminal sequences of RXRa could alter
its subcellular localization, conferring its ability to interact with
p85a.
In an effort to study the regulation of tRXRa production, we
found that expression of the N-terminal region of RXRa, RXRa/
1-134, enhanced the tRXRa level (Figure S4B). To study the bio-
logical function of the endogenous tRXRa, we stably expressed
RXRa/1-134 in HeLa cells, which resulted in production of a564 Cancer Cell 17, 560–573, June 15, 2010 ª2010 Elsevier Inc.significant amount of 44 kDa tRXRa protein. Compared with
parental HeLa cells, HeLa/RXRa/1-134 stable clone had much
higher AKT activation (Figure 4C) and was able to rapidly grow
in soft agar (Figure 4D). Sulindac strongly reduced colonies
formed by the stable clone in the colony formation assay
(Figure 4E). Together, these results demonstrate that tRXRa
may contribute to the growth and survival of cancer cells by acti-
vating AKT and that tRXRa-mediated activities can be negatively
regulated by Sulindac.
To study the possible pathological function of tRXRa, we
examined its expression in tumor tissues. Immunoblotting of
tissue samples showed the presence of tRXRa in breast and liver
cancer tissues but not in tumor surrounding tissues or distant
normal tissues from the same patients (Figure 4F). Previous
studies revealed an extensive cytoplasmic RXRa immunostain-
ing in malignant human prostatic tumor (Zhong et al., 2003)
and thyroid tumor (Takiyama et al., 2004) specimens. Immuno-
histochemical analysis using the DN197 antibody also revealed
a strong cytoplasmic RXRa staining in liver tumor tissue but
not in the surrounding tissue (Figure 4G), confirming that tRXRa
produced in tumor tissues is cytoplasmic. Together, these
results suggest that tRXRa may play a role in the development
of cancer through its ability to activate AKT.
Figure 4. Role of tRXRa in AKT Activation
and Anchorage-Independent Cell Growth
(A) Cell density dependent production of tRXRa
and AKT activation. MEFs seeded at different
cell density were analyzed for RXRa expression
using DN197 antibody and for AKT activation by
immunoblotting.
(B) Subcellular localization of endogenous RXRa in
MEFswas visualized by confocal microscopy after
immunostaining with anti-RXRa (DN197). Cells
were also stained with DAPI to visualize the
nucleus. More than 60% of cells showed the
images presented.
(C) Stable expression of RXRa/1-134 induces
RXRa cleavage and AKT activation. HeLa or
HeLa cells stably expressing RXRa/1-134 were
treated with 9-cis-RA for 30 min and analyzed for
AKT activation and expression of RXRa.
(D) Growth of HeLa/RXRa/1-134 and HeLa cells in
soft agar.
(E) Sulindac inhibits clonogenic survival of HeLa/
RXRa/1-134 cells. Cells grown in 6-well plates
for 5 days were treated with Sulindac (25 mM) for
3 days.
(F) Production of tRXRa in human tumor tissues of
breast (five out of six) or liver (four out of six)
compared with tumor surrounding and normal
tissues.
(G) Cytoplasmic localization of RXRa in liver tumor
specimens immunostained by DN197 antibody. T,
tumor tissue; S, tumor surrounding tissue. One of
three to five similar experiments is shown. See
also Figure S4.
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Activation of the PI3K/AKT Pathway and Promotes
Cancer Cell Growth and Survival
To directly address the role of N-terminally truncated RXRa, we
constructed a RXRa mutant lacking its N-terminal 80 amino
acids (RXRa/D80) with a molecular weight similar to the endog-
enous tRXRa. Also similar to tRXRa, RXRa/D80 interacted with
p85a, which was strongly enhanced by TNF-a (Figure 5A). In
contrast, the full-length RXRa did not interact with p85a either
in the absence or presence of TNF-a, suggesting that the
N-terminal sequences of RXRa prevented its binding to p85a.
Interestingly, RXRa mutant lacking the N-terminal 100 amino
acids (RXRa/D100) was unable to interact with p85a (Figure 5A).
RXRa/1-134 but not RXRa/223-462 could interact with p85aCancer Cell 17, 560–5(Figure 5B). RXRa/D80 but not RXRa/
D100 strongly activated AKT in different
cell types (Figure 5C), demonstrating
the role of RXRa/D80 in AKT activation.
Consistent with cytoplasmic localization
of tRXRa (Figure 4B and Figure S4A),
RXRa/D80 predominantly resided in the
cytoplasm, with occasional punctate
plasma membrane localization (Fig-
ure 5D). Thus, deletion of the N-terminal
sequences of RXRa alters its subcellular
localization and confers its ability to
interact with p85a.To determine how tRXRa/p85a interaction induced AKT acti-
vation, we examined whether RXRa/D80 immunocomplex
possessed PI3K activity in vitro. The PI3K activity exhibited by
theMyc-RXRa/D80 immunocomplexwasdramatically enhanced
by TNF-a treatment (Figure 5E and Figures S5A and S5B), which
correlatedwell with its ability to interact with p85a (Figure 5A) and
activation of AKT (Figure 5C). Thus, TNF-a-induced tRXRa/p85a
interaction can activate the PI3K/AKT signaling.
To further study the role of tRXRa, we stably expressed RXRa/
D80 in SW480 and HCT116 colon cancer cells. The resulting
stable cells, SW480/RXRa/D80 and HCT116/RXRa/D80,
showed elevated AKT activation and induction of its downstream
targets c-Myc and cyclin D1 (Figure 5F) and increased clono-
genic survival than do the control cells (Figure 5G). We then73, June 15, 2010 ª2010 Elsevier Inc. 565
Figure 5. Role of N-Terminally Truncated RXRa in PI3K/AKT Activation by TNFa and Cancer Cell Growth
(A) HEK293T cells were transfected with Flag-p85a and RXRa, RXRa/D80, or RXRa/D100 tagged with the Myc epitope, treated with TNFa (10 ng/ml) for 30 min,
and analyzed by coimmunoprecipitation with anti-Flag antibody.
(B) N-terminal A/B domain of RXRa interacts with p85a. Flag-p85a was cotransfected with GFP-RXRa/1-134 and GFP-RXRa/223-462 into HEK293T cells, and
analyzed for their interaction by coimmunoprecipitation with anti-Flag antibody.
(C) RXRa/D80 is a potent AKT activator. AKT activation of the indicated cells transfected with RXRa/D80 or RXRa/D100 was determined by
immunoblotting.
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animals by injecting the same number of RXRa/D80 expressing
cells and the control cells into different flanks of same nude
mice. Our results showed that tumors formed by SW480/
RXRa/D80 and HCT116/RXRa/D80 cells grew much faster than
those formed by the control cells (Figures 5H and 5I). Together,
these results demonstrate that the N-terminally truncated RXRa
is a potent promoter of cancer cell growth.
Sulindac Activates TNF-a-Induced Extrinsic Apoptotic
Pathway
We next determined whether and how synergistic inhibition
of AKT activation by Sulindac and TNF-a induced apoptosis.
Treatment of various cancer cell lines with Sulindac and TNF-a
effectively induced PARP cleavage and caspase-8 activation
(indicated by cleaved caspase-8 products, p43/p41 and p18),
whereas treatment of these cells with either Sulindac or TNF-a
alone had little effect (Figure 6A and Figure S6). The apoptotic
effect of Sulindac/TNF-a combination was partially suppressed
by RXRa-selective ligand SR11237 (Figure 6A) or transfection
of RXRa siRNA (Figure 6B).
Our observation that Sulindac/TNF-a activated caspase-8
suggested that apoptosis induction might be due to the activa-
tion of TNF-a-mediated extrinsic apoptotic pathway. To address
this, we treated cells with the caspase-8 inhibitor Z-IETD-fmk or
with caspase-8 siRNA and observed suppression of Sulindac/
TNF-a-induced PARP cleavage (Figures 6C and 6D and Figures
S6B–S6D). Thus, Sulindac/TNF-a-induced apoptosis is medi-
ated by the extrinsic apoptotic pathway.
We also examined whether Sulindac/TNF-a activation of the
extrinsic apoptotic pathway resulted in Bax activation by
immunostaining cells using conformation-sensitive Bax/6A7
antibody. Significant activated-Bax staining was observed only
when cells were treated with both TNF-a and Sulindac (Fig-
ure 6E). Crosstalk between extrinsic and intrinsic apoptotic path-
ways can be linked through Bid cleavage and activation (Li et al.,
1998). Indeed, we observed that Bid was significantly degraded
in cells treated with TNF-a and Sulindac (Figure 6A), suggesting
that Sulindac/TNF-a-induced Bax activation might be mediated
through Bid activation.
Our observation that Sulindac/TNF-a combination synergisti-
cally induced apoptosis and inhibited AKT activation suggested
that AKT activity might be critical for their induction of
apoptosis. Indeed, Sulindac/TNF-a-induced PARP cleavage
was inhibited by the expression of a constitutive-active AKT
(CA-AKT) and enhanced by the expression of a dominant-nega-
tive AKT (DN-AKT) (Figure 6F). Consistently, induction of
apoptosis and activation of caspase-8 and Bax by Sulindac/
TNF-a combination were inhibited by CA-AKT (Figures 6G and
6H, and Figure S6E). To study how Sulindac promoted(D) Cytoplasmic colocalization of RXRa/D80 and p85a. Myc-RXRa/D80 and p85a
and anti-p85a antibody, and their subcellular localization revealed by confocal m
cells. Approximately 15% of cells showed the images presented.
(E) Activation of PI3K by RXRa/D80 immunoprecipitates. A549 cells transfected
immunoprecipitated with anti-Myc antibody, and subjected to in vitro PI3K assa
(F) AKT activation by stable expression of RXRa/D80. Cells stably transfected w
(G) RXRa/D80 promotes clonogenic survival of cancer cells grown in 6-well plat
(H and I) RXRa/D80 promotes cancer cell growth in nude mice (n = 6) for 3 weeks
See also Figure S5.apoptosis through its inhibition of AKT, we examined the
expression of c-FLIP, a downstream target gene of AKT
signaling (Panka et al., 2001), which acts as a potent inhibitor
of the extrinsic apoptotic pathway by inhibiting caspase-8 acti-
vation (Irmler et al., 1997). Treatment of cells with TNF-a resulted
in strong induction of both the short form (c-FLIPS) and long
form (c-FLIPL) of c-FLIP, which was inhibited by Sulindac
(Figure 6I). Thus, Sulindac might induce apoptosis by suppress-
ing the induction of c-FLIP expression by TNF-a.
Design and Synthesis of RXRa-Selective Sulindac
Analogs
Our finding that RXRa served as an intracellular target of
Sulindac action provided an opportunity to design RXRa-selec-
tive Sulindac derivatives for cancer therapy. Thus, we conducted
docking of Sulindac to three-dimensional structures of the RXRa
LBD to identify strategies for structural modifications of Sulindac
in order to dissociate its COX inhibition from RXRa-binding
activity. Docking of Sulindac to RXRa (Figure 7A) showed that
Sulindac bound in a mode where its carboxylate group was
aligned with the carboxylate group found in all RXRa ligands
examined (Figure 7B), interacting with Arg316 in the RXRa LBP.
The benzyl methyl sulfide portion of Sulindac bound to the
hydrophobic region of the RXRa LBP, overlappingwith the a-ion-
one ring of 9-cis-RA. In this binding mode, van der Waals inter-
action of the –SCH3 group at position 4 (Figure 7C) with the
RXRa protein was not optimal and there was room around it
for modification to improve the binding to RXRa. The idea of
making use of position 4 to design RXRa-selective analogs
was fully supported by the fact that Sulindac prodrug sulindac
sulfoxide and the metabolite sulindac sulfone show no COX-in-
hibiting activity, whereas the metabolite sulindac sulfide (used
in this study) is a potent COX inhibitor (Haanen, 2001). As shown
in Figure 7A, the carboxylate group of Sulindac was positioned
away from Arg316 compared with the equivalent ones in RXRa
ligands DHA, BMS649, and 9-cis-RA. Replacing –CH2COOH at
position D with a bulkier group such as –CH2CH2COOH would
help place the carboxylate group closer to Arg316 to achieve
good charge-charge interaction with RXRa as observed in
9-cis-RA. Our candidate compounds were also examined by
docking to the crystal structure of COX-2 (Kurumbail et al.,
1996) (Figure S7) to identify non-COX binders. Based on these
considerations, five analogs were designed and synthesized
(Figure 7C and Figure S7). Their evaluation showed that all
analogs retained RXRa-binding activity, with K-80003 being
the most potent, likely due to its isopropyl group at position 4,
which has improved interaction with the hydrophobic residues
on Helix 7 of RXRa. Significantly, K-80003 and K-80005 had no
detectable inhibition of COX activities and failed to inhibit consti-
tutive and TNF-a- or interleukin-1b-induced prostaglandin E2were cotransfected into the indicated cell lines, immunostained with anti-Myc
icroscopy. RXRa/D80 predominantly resided in the cytoplasm of about 80% of
with Flag-p85a and Myc-RXRa/D80 were treated with TNFa and/or Sulindac,
y.
ith GFP-RXRa/D80 or control GFP vector were analyzed by immunoblotting.
es for 8 days.
. One of three to five similar experiments is shown. Error bars represent SEM.
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Figure 6. Activation of TNFa-Induced Extrinsic Apoptotic Pathway by Sulindac
(A) Synergistic induction of apoptosis by Sulindac/TNFa combination and its inhibition by RXRa ligand. HepG2 cells cultured inmediumwith 1%FBSwere treated
with SR11237 (1 mM) for 1 hr, then TNFa (10 ng/ml) and/or Sulindac (75 mM) for 4 hr, and analyzed by immunoblotting.
(B) Inhibition of Sulindac/TNFa-induced caspases-8 cleavage by RXRa siRNA. HepG2 cells transfected with control or RXRa siRNA were treated with TNFa
and/or Sulindac and analyzed by immunoblotting.
(C and D) Inhibition of Sulindac/TNFa-induced PARP cleavage by caspase-8 inhibitor and siRNA. HepG2 cells transfected with control or caspase-8 siRNA or
pretreated with Z-IETD-fmk (40 mM) for 1 hr were treated with TNF-a and Sulindac and analyzed by immunoblotting.
(E) Activation of Bax by Sulindac and TNFa. HepG2 cells treated with TNFa and/or Sulindac were immunostained with Bax/6A7 antibody. About 15% Sulindac-
treated cells while about 60% Sulindac/TNF-a-treated cells showed Bax staining.
(F) Regulation of Sulindac/TNFa-induced PARP cleavage by AKT. PC3 cells transfected with CA-AKT or DN-AKT were treated with TNFa and/or Sulindac, and
analyzed by immunoblotting.
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Figure 7. Design, Synthesis, and Evaluation
of RXRa-Selective Sulindac Analogs
(A) Docking of sulindac sulfide (magenta) to the
LBP of RXRa in reference to 9-cis-RA (green).
Side chains within 4 A˚ of the ligands are displayed
in gray.
(B) Comparison of orientation and position of
docked sulindac sulfide (magenta) to the crystal
structures of 9-cis-RA (green), DHA (red) and
BMS649 (blue).
(C) RXRa binding and inhibition of COX-1 and
COX-2 activities by Sulindac analogs. RXRa
binding was measured by competition ligand-
binding assays. COX inhibition assays used Cay-
man’s COX Fluorescent Activity Assay Kits.
(D) Inhibition of PGE2 production by Sulindac and
analogs. A549 cells stimulatedwith TNFa (10 ng/ml)
for 24 hr were treated with Sulindac or analogs for
30 min. PGE2 production was measured and ex-
pressed as the ratio of PGE2 produced in the pres-
ence of compound to that with vehicle. Error bars
represent SEM.
(E) Comparison of 19F NMR spectra of K-80003
(100 mM) in the absence and presence of 10 mM
RXRa LBD. One of three to five similar experi-
ments is shown. See also Figure S7.
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Truncated RXRa and Ligands in PI3K-AKT Signaling(PGE2) production (Figures 7C and 7D, and data not shown). The
binding of K-80003 to RXRa was also confirmed by 19F NMR
binding assays (Figure 7E). Thus, Sulindac’s RXRa-binding can
be dissociated from its COX-binding.RXRa-Selective Analog K-80003 Is a Potent Inhibitor
of AKT Activation and Cancer Cell Growth
Because of its much-improved affinity to RXRa and lack of COX
inhibitory effect, K-80003 was chosen for further evaluation.
Immunoblotting showed that K-80003 was much more effective
than Sulindac in inhibiting RA- and TNFa-induced AKT activation
(Figure 8A and Figure S8). The inhibitory effect of K-80003 on
AKT activation in PC3 cells is largely impaired by reducing
RXRa, but not RARg, expression by siRNA (Figure 8B). Thus,
inhibition of AKT activation by K-80003 was also dependent on
RXRa expression. The interaction of RXRa/D80 with p85a either
in the absence or presence of TNFa was more potently inhibited
by K-80003 than by Sulindac (Figure 8C). K-80003 was also
more effective than Sulindac in inducing PARP cleavage when(G and H) CA-AKT inhibits activation of caspase-8 (G) and Bax (H) by Sulindac and TNF-a. HepG2 cells tran
Sulindac, and immunostained with anti-cleaved caspase-8 or Bax/6A7 antibody. About 80% nontransfec
caspase-8 staining. Approximately 60% nontransfected and about 13% CA-AKT-transfected cells exhibited
(I) Regulation of c-FLIP expression by TNFa and Sulindac. Cells treated with TNFa and/or Sulindac for 6 hr we
similar experiments is shown. See also Figure S6.
Cancer Cell 17, 560–5used together with TNFa in ZR-75-1 cells
(Figure 8D). Similar to Sulindac, K-80003
combination with TNF-a synergistically
induced PARP cleavage and caspase-8
activation (Figure 8E). In clonogenic
survival assays, colony formation of
HeLa/RXRa/1-134 and RXRa/D80 cells
was almost completely suppressed byK-80003 (Figure 8F). Significantly, K-80003 exhibited much
more potent inhibitory effect than Sulindac on the growth of
RXRa/D80 tumor in animals (Figure 8G). Together, the RXRa-
selective Sulindac analog K-80003 is a potent inhibitor of
RXRa-mediated PI3K/AKT signaling and cancer cell growth.
DISCUSSION
RXRa is an attractive molecular target for drug development.
Here, we report that Sulindac could bind to RXRa in the range
of concentrations commonly used to study the anticancer
effects of Sulindac. Conventional administration of Sulindac
could result in about 10–15 mM Sulindac in the serum of patients
and up to 50 mM Sulindac could be detected in the plasma of
humans (Yamamoto et al., 1999). Sulindac could be also
concentrated in epithelial cells at concentrations that are at least
20-fold higher than those in the serum (Duggan et al., 1980).
Thus, the binding affinity of Sulindac to RXRa is relevant to
in vivo cancer prevention by this drug. The findings that Sulindacsfected with CA-AKT were treated with TNFa and
ted and 15% CA-AKT-transfected cells showed
Bax staining.
re analyzed by immunoblotting. One of three to five
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Figure 8. K-80003 Is a Potent Inhibitor
of RXRa Dependent AKT Activation
(A) Inhibition of AKT activation by Sulindac (50 mM)
or K-80003 (50 mM) in the presence of TNF-a.
(B) RXRa-dependent inhibition of AKT activation
by K-80003. PC3 cells transfected with RXRa or
RARg siRNA were pretreated with K-80003
(50 mM) for 1 hr before exposed to TNF-a (10 ng/ml)
for 30 min. pRXRa: phosphorylated RXRa.
(C) Inhibition of RXRa/D80 interaction with p85a by
Sulindac and K-80003. A549 cells were trans-
fected with Flag-p85a and Myc-RXRa/D80,
treated with Sulindac (50 mM) or K-80003 (50 mM)
for 1 hr before exposed to TNF-a for 30 min, and
analyzed by coimmunoprecipitation with anti-
Flag antibody.
(D) Induction of PARP cleavage by Sulindac or
K-80003 in the presence of TNF-a. ZR-75-1 cells
treated with TNFa and/or Sulindac (75 mM) or
K-80003 (50 mM) for 6 hr were analyzed by immu-
noblotting.
(E) Activation of caspase-8 by K-80003 in the
presence of TNF-a. Cells treated with TNFa and/or
K-80003 (50 mM) were analyzed by immunoblot-
ting.
(F) Inhibition of clonogenic survival of RXRa/1-134
cells and RXRa/D80 stable clones by Sulindac
(25 mM) and K-80003 (25 mM).
(G) Inhibition of RXRa/D80 tumor growth in animals
bySulindac andK-80003.Mice (n = 6) were treated
intraperitoneally with corn oil, Sulindac (60mg/kg),
or K-80003 (60 mg/kg) for 2 weeks. Tumors were
removed and measured. Error bars represent
SEM. One of three to five similar experiments is
shown. See also Figure S8.
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largely depends on RXRa expression and its intact LBP strongly
suggest that RXRa is an intracellular target of Sulindac.
An important finding of this study is that the N-terminally
truncated RXRa protein acts differently from the full-length
RXRa protein. Cytoplasmic tRXRa interacted with p85a to
activate the PI3K/AKT survival pathway and induce anchorage-
independent cell growth in vitro and tumor growth in animals,
implying that tRXRamay serve as an important tumor promoter.
Our mutational analysis suggested that amino acids from 80 to
100 in RXRa are critical for tRXRa binding to p85a. The region
is enriched with proline resides, which can presumably form
several polyproline helices (PPII helix) known to bind to
the SH3 domain (Kaneko et al., 2008) that is present in p85a.
The p85a-binding motif(s) in RXRa are probably masked by the
N-terminal end sequences and regulated by phosphorylation.
This is consistent with the regulation of tRXRa production and
AKT activation by cell density. Regulated proteolysis is a key570 Cancer Cell 17, 560–573, June 15, 2010 ª2010 Elsevier Inc.step in a number of different signaling
pathways. Caspase-mediated cleavage
of the BH3-only protein Bid into a trun-
cated protein (tBid) and subsequent
translocation of tBid to mitochondria are
implicated in death receptor signaling (Li
et al., 1998), whereas proteolytic pro-
cessing of Notch and nuclear transloca-tion of truncated product are crucial steps in transduction of
the Notch signaling (Ye et al., 1999). STAT signaling is also regu-
lated by proteolytic processing (Hendry and John, 2004). Thus,
cleavage of RXRamay represent a mechanism that triggers non-
genomic tRXRa signaling by removing the inhibitory N-terminal
domain, allowing tRXRa to expose its p85a-binding motif and
activate the PI3K/AKT signaling.
Our finding that tRXRa is produced in tumor tissues but not in
normal tissues is consistent with previous findings that RXRa is
cleaved in tumor but not in premalignant or normal tissues
from patients with prostate or thyroid cancer (Takiyama et al.,
2004; Zhong et al., 2003). Thus, agents targeting tRXRa-medi-
ated pathway can be effective and tumor specific. To this end,
we showed that Sulindac could inhibit the tRXRa-mediated
PI3K/AKT activation, suggesting that Sulindac represents
a lead for a class of anticancer agents targeting this pathway.
Our observation that Sulindac and TNFa synergistically inhibit
tRXRa-dependent AKT activation provides insight into the
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Truncated RXRa and Ligands in PI3K-AKT Signalingcrosstalk between retinoid receptor and TNFa signaling path-
ways. Retinoids in combination with cytokines, such as TNFa
and TNF-related apoptosis inducing ligand (TRAIL), can syner-
gistically induce differentiation or apoptosis of human trans-
formed cells (Altucci et al., 2005), whereas combination of reti-
noids and TNFa can overcome RA resistance (Witcher et al.,
2004). The fact that Sulindac and TNFa synergistically inhibit
AKT activation in cancer cells implies that TNFa and probably
other cytokines can prime cancer cells for their responsiveness
to RXRa ligands such as Sulindac by converting AKT activation
from a RXRa-independent to a RXRa-dependent manner.
TNFa plays important roles in diverse cellular events such as
cell survival and death. However, it often fails to induce
apoptosis in cancer cells because of its simultaneous activation
of the NF-kB and/or the PI3K/AKT pathway (Aggarwal, 2003;
Balkwill, 2009). Our observation that tRXRa mediates AKT
activation by TNFa suggests a possibility of using Sulindac or
analogs to suppress TNFa-induced AKT-mediated survival
function, thereby shifting its function from survival to death.
Consistently, we have provided evidence that Sulindac in combi-
nation with TNFa potently induce tRXRa-dependent caspase-8
activation and apoptosis, demonstrating that Sulindac is able
to sensitize cancer cells to TNFa-induced death receptor-medi-
ated extrinsic apoptotic pathway. The fact that TNFa-induced
c-FLIP expression is completely prevented by Sulindac places
c-FLIP in a central position for integrating TNFa-induced AKT
activation and its inhibition by Sulindac and induction of
apoptosis by Sulindac and TNFa combination.
Our finding that RXRa serves as an intracellular target of
Sulindac action provides a rationale to design RXRa-selective
Sulindac derivatives for suppressing AKT activity. Our identifica-
tion of a Sulindac analog, K-80003, with improved affinity to
RXRa but lacking COX inhibitory effects offers an example to
this approach. It is expected that K-80003 will lack or have
much reduced COX-2-associated side effects. The fact that
K-80003 could effectively inhibit the tRXRa pathway and the
growth of cancer cells in vitro and in animals warrants its further
development for cancer therapy.
EXPERIMENTAL PROCEDURES
Plasmids
Flag-p85a, RXRa/F313S/R316E, RXRa/D80, and RXRa/D100 were con-
structed with standard methods.
Antibodies and Reagents
Antibodies for pAkt (Ser473, D9E), Bid, and cleaved caspase-8 (p43/p41)
(Cell Signaling); Flag (M2), and Bax(6A7) (Sigma-Aldrich); p85a (Millipore);
AKT1(C-20), GFP(B-2), Hsp60(N-20), c-Myc(9E10), RARg(C-19), RXRa(D20),
RXRa(DN197), Bax(D21), c-FLIP, PARP(H-250) (Santa Cruz Biotechnology)
were used. Sulindac and analogs were dissolved in dimethyl sulfoxide.
Ligand Binding Assay
RXR LBD was incubated with [3H]-9-cis-RA in the presence or absence of
unlabeled 9-cis-RA or Sulindac. Bound [3H]-9-cis-RA was determined.
HPLC Analysis of Sulindac Binding
HEK293 cells stably transfected with vector containing receptor fused to
C-terminal TAP fusion were treated with or without 100 mM Sulindac for 3 hr.
Receptor proteins purified with InterPlay Mammalian TAP System (Stratagene)
were analyzed by HPLC using microsorb-mv 100-3 C18 100 3 4.6 column(Varian). Sulindac was detected with a photoarray detector (Waters model
2996). A standard solution of Sulindacwas used to obtain the calibration curve.
Proteolytic Protection Assay
In vitro translated [35S]-labeled RXRa-LBD or GST-RXRa was incubated with
solvent or Sulindac (100 mM) for 30 min and then digested with chymotrypsin.
NMR Binding Assays
19F NMR Spectra on Bruker Avance 500 NMR Spectrometer with a F-H-D-O
probe were recorded with 1024 transients using a sweep width of 18797 Hz.
The repetition time was 2 s.
Apoptosis Assays
Apoptosis assays followed those described elsewhere (Kolluri et al., 2008;
Li et al., 2000; Lin et al., 2004).
Bax Oligomerization Assay
Lysates were incubated with BMH (Pierce) to crosslink the oligomerized Bax
protein. For studying Bax oligomerization on mitochondria, heavy membrane
fractions were lysed for immunoblotting with anti-Bax antibody (Bax 2D2).
siRNA
RXRa (M-003443-02) and RARg (M-003439-01) siRNA siGENOME
SMARTpool, Caspase-8 siRNA ON-TARGETplus siRNA (J-003466-14), and
siRNA Nonspecific Control IX (D-001206-09-05) were from DHARMACON.
Coimmunoprecipitation and Immunoblotting Assays
The assays followed those described previously (Li et al., 2000; Lin et al., 2004).
Confocal Microscopy
Cells seeded on chamber slides were fixed, permeabilized, and stained with
appropriate antibodies (Li et al., 2000).
PI3K Kinase Assay
Cells transfected with Flag-p85a and Myc-RXRa/D80 were serum-starved for
4 hr, pretreated with Sulindac for 0.5 hr, and TNF-a for 15 min. Cell lysates
immunoprecipitated with anti-Myc antibody were incubated with phosphati-
dylinositol and [g-32P] ATP and subjected to thin-layer chromatography.
Stable Transfection and Soft Agar Assay
RXRa/1-134 cloned into pNTAP vector was stably transfected into HeLa cells,
while GFP-RXRa/D80 was stably transfected into SW480 and HCT116 cells.
Cells seeded at 53 103 cells/well (6-well plate) in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum (FBS) and 0.35% agarose
with 0.5% bed agar for 12 days were stained with 0.005% crystal violet.
Colony Formation Assay
Cells were seeded in 6-well plate for 5 days, treated with compound in 0.5%
serum medium for 3 days, and fixed with 4% paraformaldehyde. Colonies
were stained with 0.1% crystal violet.
Human Tissues and Evaluation
Breast and liver tumor tissues and their surrounding tissues were obtained by
surgical resection from cancer patients. Histological normal specimens, which
were about at least 35 cm distant from the tumor nodule, were obtained from
the corresponding patients. The study was approved by Xiamen University
Institute for Biomedical Research Ethics Committee, and all of the patients
gave informed consent. Tissues with primary hepatocellular carcinoma
(HCC, n = 6) or breast cancer (n = 6) were collected for detecting the expres-
sion of RXRa using DN197 antibody. For immunohistochemistry analysis,
tissue sections were incubated with the DN197 antibody (1:500) overnight at
4C and detected with goat anti-rabbit-specific immunoglobulins (1:100).
The slides were counterstained with hematoxylin.
COX Assays
COX Fluorescent Activity Assay, COX Fluorescent Inhibitor Screening
Assay, and Prostaglandin E2 Enzyme Immunoassay Kits were from CaymanCancer Cell 17, 560–573, June 15, 2010 ª2010 Elsevier Inc. 571
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Truncated RXRa and Ligands in PI3K-AKT SignalingChemical. Assays were performed in accordance with the manufacturer’s
protocols.
Animal Studies
Nude mice (BALB/c, 4–5 weeks old) were injected subcutaneously with 100 ml
cells (2 3 106). For drug treatment, mice (n = 6) were treated intraperitoneally
after 7 days of transplantation with Corn oil, Sulindac (60 mg/kg), or K-80003
(60 mg/kg) once every other day (six injections). Body weight and tumor sizes
were measured every 4 days. All manipulations involving live mice were
approved by the Animal Care and Use Committee of Xiamen University.
Chemical Synthesis
Compound synthesis followed schemes in Supplemental Experimental
Procedures. 1H NMR and 13C NMR spectra, IR spectra, and mass spectra
were recorded on Bruker 400 AV spectrometer, Nicolet Avatar 360 FT-IR
spectrophotometer, and Bruker Dalton Esquire 3000 plus or a Finnigan
Mat-LCQ (ESI direct injection), respectively. 1H NMR spectra were registered
in CDCl3 or DMSO-d6, and chemical shifts were expressed in parts per million
(d) relative to internal Me4Si. Elemental analyses were performed using a Vario
RL analyzer. Melting points were determined on an X-4 Micro-melting point
apparatus and were uncorrected.
Statistical Analyses
Data were analyzed using an analysis of variance or Student’s t test and were
presented as the mean and standard error of the mean (±SEM).
SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.ccr.2010.04.023.
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